6505--ME/ New Pluvicto Theronastic Therapy Radiopharmaceuticals/STL(VA-26-00053903) 657-26-4-1642-0063
Veterans Affairs · 255-NETWORK CONTRACT OFFICE 15 (36C255)
No listed company matched (Materiality N/A)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 36C25526N0394 in this department, oldest first.
- Aug 21, 2026 · this noticeAward NoticeNovartis Pharmaceuticals Corporation · $892K
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Note the winner and the end of the period of performance for the recompete.
- Follow the agency to see the next notice for this work.
What the notice says
Ordering Activity / Contracting Office Department of Veterans Affairs Network Contracting Office (NCO 15) 3450 S 4th Street Trafficway Leavenworth, KS 66048 Contract / Order Information FSS Contract Number: 36F79720D0180 Order Number: 36C25526N0394 Requisition / PO Number: 657-C60305 Effective Date of Award: August 5, 2026Ordering Period: August 5, 2026 through February 5, 2027 Method of Solicitation: FSS order under SF 1449, commercial products and commercial services Awardee (Contractor) Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 UEI: NG61ZA8TADW3 (as shown on th… (show all)
e SF 1449). Primary Contractor POC: Yisell Rodriguez, 201 602 5055, yisell.rodriquez@novartis.com. Place of Delivery / Performance VA St. Louis Health Care System John J. Cochran Veterans Hospital 915 North Grand Boulevard St. Louis, MO 63106 Description of Supplies/Services This award provides one proprietary radiopharmaceutical agent, PLUVICTO (Lutetium Lu 177 vipivotide tetraxetan), NDC 69488 0010 6, for use by Nuclear Medicine at VA St. Louis Health Care System. PLUVICTO is indicated for adult patients with PSMA positive metastatic castration resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane based chemotherapy. The period of performance supports diagnostic and therapeutic use of this radiopharmaceutical in accordance with the Statement of Work included in the SF 1449. Line Item and Pricing CLIN 0001: PLUVICTO Lutetium Lu 177 vipivotide tetraxetan, NDC 69488 0010 6. Quantity: 26 Each. Unit Price: 34,294.26. Extended Amount: 891,650.76. Total Award Amount: 891,650.76. Funding / Accounting Data As shown on SF 1449: 657 26 4 1642 0063 / 657 3660 / 160 1642 822900 2580 / 0100L00H6 (Accounting and Appropriation Data). Invoice and Payment Instructions Invoices shall be submitted monthly in arrears and must reference PO number 657 C60305 and Order number 36C25526N0394. All invoices shall be submitted electronically in accordance with VAAR 852.232 72, via the VA Financial Services Center e-invoicing system (Austin, TX). Payment will be made by: Department of Veterans Affairs Financial Services Center, Austin, TX (see SF 1449 Block 18a and Continuation Page for full details). Contract Administration / Points of Contact Contracting Officer: Michael P. Murphy Department of Veterans Affairs Network Contracting Office (NCO 15) 3450 S 4th Street Trafficway, Leavenworth, KS 66048 Email: michael.murphy7@va.gov Phone: 913 946 1970 Facility Point of Contact (Pluvicto): Mark Lauridsen VA St. Louis Health Care System Email: mark.lauridsen@va.gov Phone: 314 652 4100 ext. 66522 The Contracting Officer retains sole authority to approve changes or modifications affecting price, quantity, or quality of performance under this contract. The Contracting Officer s Representative (COR) will be designated separately in accordance with VAAR 852.270 1 and will be responsible for technical and administrative oversight. Special Terms and Conditions This order is subject to the terms and conditions of FSS Contract 36F79720D0180 and all clauses incorporated by reference on SF 1449, including VAAR 852.247 71 (Delivery Location), VAAR 852.232 72 (Electronic Submission of Payment Requests), VAAR 852.203 70 (Commercial Advertising), VAAR 852.242 71 (Administrative Contracting Officer), and VAAR 852.246 71 (Rejected Goods). The VA St. Louis Health Care System s business hours and applicable federal holidays are as set forth in the Statement of Work, and contract performance monitoring will be conducted in accordance with VA quality assurance procedures described therein.
Who won similar work
3 award notices on SAM.gov in the last 24 months. Matched by: Same office (255-NETWORK CONTRACT OFFICE 15 (36C255)), same NAICS 325412.
Single-winner award sizes (3): middle half $547K to $1.0M, median $737K; range $358K to $1.4M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| SOFIE Co. DULLES 20166 | 1 | $1.4M | Jan 12, 2026 |
| Novartis Pharmaceuticals Corporation | 1 | $737K | Aug 11, 2025 |
| OPTUM INFUSION SERVICES 308, LLC | 1 | $358K | Aug 31, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Aug 31, 2026OPTUM INFUSION SERVICES 308, LLC$358KQ517--36C25526D0052 | Pharmacy Compounded Sterile Preparation (CSP) Contingency | Optum Infusion Services 308, LLC | VISN 15 | 09/01/2026 - 08/31/2031 |No listed company matched (Materiality N/A)
- Jan 12, 2026SOFIE Co. DULLES 20166$1.4M6505--36C25526D0024 PET/CT Doses - KC VAMCNo listed company matched (Materiality N/A)
- Aug 11, 2025Novartis Pharmaceuticals Corporation$737K6505--Pluvicto, STL 36C255-25-AP-0008No listed company matched (Materiality N/A)
Competitive landscape
For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (0 filings)
- 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 25 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.